Sophiris Bio (SPHS) Stock Price, News & Analysis

Company Overview

Sophiris Bio, Inc. was a biotechnology company focused on developing locally administered therapies for urological diseases. The company’s research centered on treatments intended to address conditions affecting the prostate while limiting exposure to healthy tissue.

Sophiris’ primary product candidate was topsalysin, also known as PRX302, a recombinant protein therapy designed to be activated within prostate tissue. The company investigated topsalysin as a potential treatment for benign prostatic hyperplasia, a common condition that can cause urinary symptoms, and for localized prostate cancer.

The company was formerly known as Protox Therapeutics and adopted the Sophiris Bio name as it advanced its urology-focused development programs. Publicly available information about its later operations, leadership, geographic activities and commercial status is limited, and the company’s programs were primarily associated with clinical-stage research rather than marketed products.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $4 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 11/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:SPHS
• CIK: 1563855
• Web: www.sophirisbio.com
• Phone: (858) 777-1760
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 35,550,000
• Free Float: N/A
• Market Cap: $4 thousand
• Optionable: Not Optionable
• Beta: 1.94